Urine Cadmium Levels in Predicting Pancreatic Cancer Risk in Patients With Chronic Pancreatitis
Study Details
Study Description
Brief Summary
RATIONALE: Measuring cadmium levels in urine samples from patients with chronic pancreatitis may help doctors predict which patients may develop pancreatic cancer. It may also help the study of cancer in the future.
PURPOSE: This clinical trial is studying urine cadmium levels in predicting pancreatic cancer risk in patients with chronic pancreatitis.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
OBJECTIVES:
Primary
-
Obtain urine samples and questionnaire data on cadmium exposure in patients with chronic pancreatitis.
-
Analyze these data to determine risk of pancreatic cancer using urine cadmium levels.
Secondary
-
Analyze these data in conjunction with data on serum CA 19-9, to determine whether urinary cadmium has clinical utility in predicting pancreatic cancer.
-
Determine the sensitivity, specificity, and positive and negative predictive values for the cadmium test alone, CA 19-9 alone, and both tests together.
OUTLINE: This is a pilot study.
Patients complete a questionnaire over approximately 20 minutes on lifetime exposure to cadmium, including dietary, occupational, and recreational exposure, smoking history, and residence. Patients also provide a urine sample that is analyzed by atomic absorption spectrophotometry. Serum CA 19-9 levels are obtained from medical record if available.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
pre cancerous condition (pancreatitis)
|
Outcome Measures
Primary Outcome Measures
- Exposure to cadmium, as measured by questionnaire data on dietary, occupational, and recreational exposure to cadmium, and by measurements of cadmium in urine [day 1]
- Risk of pancreatic cancer as determined by urine cadmium levels [day 1]
Secondary Outcome Measures
- Predictive value of urinary cadmium on development of pancreatic cancer [day 1]
- Predictive value of urinary cadmium alone, CA 19-9 alone, and both tests together on development of pancreatic cancer [day 1]
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Clinical diagnosis of chronic pancreatitis
-
Being seen in the Department of Gastroenterology at Wake Forest University Baptist Medical Center
PATIENT CHARACTERISTICS:
-
No type II diabetes
-
Able to understand and respond to questionnaire
-
Able to provide urine specimen
-
Speaks English
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
Investigators
- Study Chair: Gary G. Schwartz, MD, PhD, MPH, Wake Forest University Health Sciences
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CDR0000550074
- CCCWFU-98503
- CCCWFU-BG03-223